Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 4/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | GPR142 | Q7Z601 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9290706 | 0.93 | CREBBP (0.36) | CREBBPPIK3CAPIK3CGGPR142USP2 | |
| SCHEMBL8535612 | 0.89 | PIK3CA (0.35) | CREBBPPIK3CA | |
| SCHEMBL8535507 | 0.88 | PIK3CA (0.43) | CREBBPPIK3CA | |
| SCHEMBL8514534 | 0.86 | CREBBP (0.37) | CREBBPPIK3CAGPR142USP2POLB | |
| SCHEMBL16479946 | 0.84 | PIK3CG (0.37) | CREBBPPIK3CGUSP2POLB | |
| SCHEMBL8536906 | 0.82 | PIK3CA (0.42) | CREBBPPIK3CAPIK3CG | |
| SCHEMBL8533388 | 0.80 | PIK3CA (0.38) | CREBBPPIK3CA | |
| SCHEMBL8534481 | 0.80 | PIK3CA (0.37) | CREBBPPIK3CA | |
| SCHEMBL15514150 | 0.80 | CREBBP (0.37) | CREBBPPIK3CAGPR142 | |
| SCHEMBL16479808 | 0.80 | PIK3CG (0.33) | PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140073628-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | RICE KENNETH D (US) | 2014-03-13 | — | — | US | claimed |
| US-20140073628-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | RICE KENNETH D (US) | 2014-03-13 | — | — | US | disclosed |
| EP-2643315-A1 | BENZOXAZEPINES AS INHIBITORS OF P13K/mTOR AND METHODS OF THEIR USE AND MANUFACTURE | Exelixis, Inc. (US) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012071501-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140073628-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | MTOR, RPTOR, RICTOR | CREBBP 393/4885PIK3CA 12/4885PIK3CG 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.